A cancer research company co-founded at George Mason University has received $8.7 million in financing from a private equity firm, an infusion of capital that will connect more patients with ground-breaking personalized cancer treatments.
Four years ago, Mason researcher Emanuel “Chip” Petricoin helped found Perthera Inc., a McLean-based company, which uses technology to pinpoint cancer treatments in individual patients. This process is known as precision cancer analysis. Now, the company is getting a boost from Pilot Growth Equity, a technology growth equity firm that sees great potential in this technology.
For more information see article at https://www2.gmu.edu/news/243881.